

William Jacot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1357453/publications.pdf>

Version: 2024-02-01

79
papers

2,573
citations

218677

26
h-index

233421

45
g-index

85
all docs

85
docs citations

85
times ranked

3861
citing authors

#	ARTICLE	IF	CITATIONS
1	Sexual quality of life assessment in young women with breast cancer during adjuvant endocrine therapy and patient-reported supportive measures. <i>Supportive Care in Cancer</i> , 2022, 30, 3633-3641.	2.2	6
2	Abstract P2-01-12: Detection of circulating tumor cells in cerebrospinal fluid for patients with suspected breast cancer leptomeningeal metastases: A prospective study. <i>Cancer Research</i> , 2022, 82, P2-01-12-P2-01-12.	0.9	0
3	In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired resistance derive from quiescent residual cancer cells that overexpress <i>CRYAB</i> , <i>CEACAM6</i> and <i>SOX2</i> . <i>Journal of Pathology</i> , 2022, 257, 367-378.	4.5	11
4	Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	0
5	Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer. <i>Lancet Oncology</i> , 2022, 23, 557-558.	10.7	1
6	Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects. <i>Pharmaceutics</i> , 2022, 14, 841.	4.5	4
7	Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort. <i>International Journal of Cancer</i> , 2022, 151, 1355-1366.	5.1	9
8	Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 34.	7.1	92
9	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results. <i>Quality of Life Research</i> , 2021, 30, 91-103.	3.1	7
10	A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. <i>Theranostics</i> , 2021, 11, 6173-6192.	10.0	27
11	Exploring Sensitivity to Replicative Stress in BRCA-Deficient Triple Negative Breast Cancer. <i>Medical Sciences Forum</i> , 2021, 3, .	0.5	0
12	Clinicopathological Correlates of T Cell Infiltration in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 765.	3.7	13
13	Alpelisib for the treatment of <i>PIK3CA</i> -mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 667-675.	1.8	7
14	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021, 146, 30-47.	2.8	81
15	Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program. <i>Breast</i> , 2021, 56, 18-25.	2.2	2
16	CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers. <i>Cancers</i> , 2021, 13, 2328.	3.7	20
17	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1605-1618.	5.1	8
18	Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer. <i>BMC Cancer</i> , 2021, 21, 815.	2.6	2

#	ARTICLE	IF	CITATIONS
19	Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1503-1512.	3.2	38
20	Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 115.	5.2	33
21	Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021, 125, 1486-1493.	6.4	37
22	Prospective evaluation of sexual health in breast cancer women during the first year of adjuvant hormonal treatment using a cancer patient's dedicated questionnaire: A glaring gap of communication between health professionals and patients. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 705-713.	2.5	12
23	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, 19787.	3.3	2
24	Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers. <i>Cancers</i> , 2021, 13, 6059.	3.7	60
25	A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy. <i>Nutrients</i> , 2021, 13, 4429.	4.1	5
26	Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. <i>European Journal of Cancer</i> , 2020, 125, 22-30.	2.8	31
27	Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). <i>Angiogenesis</i> , 2020, 23, 193-202.	7.2	11
28	Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. <i>Cancers</i> , 2020, 12, 2666.	3.7	17
29	Prognostic Value of CXCR2 in Breast Cancer. <i>Cancers</i> , 2020, 12, 2076.	3.7	19
30	Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. <i>Clinical Chemistry</i> , 2020, 66, 1093-1101.	3.2	33
31	Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial. <i>Nutrients</i> , 2020, 12, 3081.	4.1	15
32	Identification of a regulatory VÎ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer. <i>Journal of Leukocyte Biology</i> , 2020, 107, 1057-1067.	3.3	27
33	Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. <i>Cancers</i> , 2020, 12, 1244.	3.7	15
34	Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008â€“2016. <i>European Journal of Cancer</i> , 2020, 129, 60-70.	2.8	103
35	Liquid chromatographyâ€“tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 188, 113438.	2.8	7
36	Diversity of Tumor-Infiltrating, Î³Î³ T-Cell Abundance in Solid Cancers. <i>Cells</i> , 2020, 9, 1537.	4.1	30

#	ARTICLE	IF	CITATIONS
37	Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. <i>Scientific Reports</i> , 2020, 10, 10757.	3.3	8
38	Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review. <i>Cancers</i> , 2020, 12, 958.	3.7	77
39	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 828.	3.7	27
40	PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 659-667.	2.5	17
41	Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial. <i>BMC Cancer</i> , 2019, 19, 737.	2.6	73
42	Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. <i>British Journal of Cancer</i> , 2019, 121, 991-1000.	6.4	113
43	Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. , 2019, 7, 29.		63
44	Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. <i>International Journal of Cancer</i> , 2019, 145, 3359-3369.	5.1	29
45	Distinct oncogenes drive different genome and epigenome alterations in human mammary epithelial cells. <i>International Journal of Cancer</i> , 2019, 145, 1299-1311.	5.1	6
46	High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker. <i>Frontiers in Oncology</i> , 2019, 9, 1141.	2.8	17
47	<p>Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10353-10373.	1.9	8
48	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 58-73.	4.4	30
49	The prognostic value of theÂTau protein serum level in metastatic breast cancer patients and its correlation with brain metastases. <i>BMC Cancer</i> , 2019, 19, 110.	2.6	20
50	Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer. <i>Journal of Neuro-Oncology</i> , 2018, 138, 369-382.	2.9	19
51	Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24.	2.8	211
52	Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 144-149.	2.4	10
53	External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience. <i>Breast</i> , 2018, 37, 36-41.	2.2	31
54	Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology. <i>Oncologist</i> , 2018, 23, 1289-1299.	3.7	31

#	ARTICLE	IF	CITATIONS
55	Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 770.	2.6	15
56	Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. <i>British Journal of Cancer</i> , 2018, 119, 76-79.	6.4	48
57	Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2~ pN0 early breast cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 611-621.	2.5	11
58	Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database. <i>Journal of Medical Economics</i> , 2017, 20, 1261-1267.	2.1	5
59	CMET-29. HORMONE RECEPTORS STATUS: A STRONG DETERMINANT OF THE KINETICS OF BRAIN METASTASES OCCURRENCE COMPARED WITH HER2 STATUS IN BREAST CANCER. <i>Neuro-Oncology</i> , 2017, 19, vi45-vi45.	1.2	0
60	Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. <i>Histopathology</i> , 2016, 68, 262-271.	2.9	22
61	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 307-318.	2.5	101
62	Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?. <i>International Journal of Cancer</i> , 2016, 139, 2299-2311.	5.1	23
63	High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 986.	2.6	19
64	Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study. <i>BMC Cancer</i> , 2015, 15, 659.	2.6	30
65	Frequent expression of PD-L1 on circulating breast cancer cells. <i>Molecular Oncology</i> , 2015, 9, 1773-1782.	4.6	303
66	Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?. <i>Future Oncology</i> , 2015, 11, 557-559.	2.4	15
67	Oncoplastic Resection of Breast Cancers Located in the Lower-Inner or Lower-Outer Quadrant with the Modified McKissock Mammoplasty Technique. <i>Annals of Surgical Oncology</i> , 2015, 22, 486-494.	1.5	9
68	Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer. <i>Clinical and Translational Medicine</i> , 2014, 3, 31.	4.0	10
69	Iron homeostasis and anemia markers in early breast cancer. <i>Clinica Chimica Acta</i> , 2014, 434, 34-40.	1.1	42
70	Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. <i>Molecular Oncology</i> , 2014, 8, 431-443.	4.6	48
71	Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases. <i>BMC Cancer</i> , 2013, 13, 70.	2.6	17
72	Adapted physical activity and diet (APAD) during adjuvant breast cancer therapy: Design and implementation of a prospective randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2013, 36, 531-543.	1.8	13

#	ARTICLE	IF	CITATIONS
73	Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and 1833-41.	2.3	14
74	Prognostic factors of brain metastases from breast cancer: Impact of targeted therapies. Breast, 2013, 22, 993-998.	2.2	25
75	BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer, 2013, 13, 523.	2.6	44
76	Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2012, 134, 709-717.	2.5	38
77	Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Research, 2011, 13, R15.	5.0	56
78	Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Research, 2011, 13, R133.	5.0	37
79	Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer, 2010, 10, 257.	2.6	14